| Analysis | Metabolite Name | Measured Value | Units | Group | TIMEPOINT |
|---|---|---|---|---|---|
| Reversed phase NEGATIVE ION MODE | urate | 0.5427 | scaled units | High-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | urate | 0.6369 | scaled units | Low-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | urate | 0.6447 | scaled units | Low-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | urate | 0.6605 | scaled units | High-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | urate | 0.6614 | scaled units | High-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | urate | 0.6838 | scaled units | High-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | urate | 0.6860 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | urate | 0.7120 | scaled units | Low-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | urate | 0.7199 | scaled units | Low-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | urate | 0.7262 | scaled units | Placebo | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | urate | 0.7266 | scaled units | Low-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | urate | 0.7383 | scaled units | High-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | urate | 0.7442 | scaled units | Low-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | urate | 0.7482 | scaled units | Placebo | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | urate | 0.7522 | scaled units | Low-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | urate | 0.7541 | scaled units | Low-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | urate | 0.7570 | scaled units | High-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | urate | 0.7574 | scaled units | Low-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | urate | 0.7580 | scaled units | Low-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | urate | 0.7581 | scaled units | High-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | urate | 0.7600 | scaled units | Placebo | -0.5HR |
| Reversed phase NEGATIVE ION MODE | urate | 0.7704 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | urate | 0.7726 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | urate | 0.7742 | scaled units | High-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | urate | 0.7761 | scaled units | High-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | urate | 0.7803 | scaled units | Placebo | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | urate | 0.7864 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | urate | 0.7942 | scaled units | Placebo | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | urate | 0.7963 | scaled units | High-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | urate | 0.7982 | scaled units | Placebo | BASELINE |
| Reversed phase NEGATIVE ION MODE | urate | 0.8157 | scaled units | Placebo | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | urate | 0.8243 | scaled units | High-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | urate | 0.8300 | scaled units | High-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | urate | 0.8300 | scaled units | Low-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | urate | 0.8308 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | urate | 0.8352 | scaled units | High-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | urate | 0.8359 | scaled units | Low-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | urate | 0.8362 | scaled units | High-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | urate | 0.8492 | scaled units | Placebo | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | urate | 0.8494 | scaled units | High-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | urate | 0.8587 | scaled units | High-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | urate | 0.8593 | scaled units | Low-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | urate | 0.8611 | scaled units | High-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | urate | 0.8758 | scaled units | High-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | urate | 0.8789 | scaled units | Placebo | BASELINE |
| Reversed phase NEGATIVE ION MODE | urate | 0.8794 | scaled units | High-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | urate | 0.8819 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | urate | 0.8822 | scaled units | High-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | urate | 0.8828 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | urate | 0.8829 | scaled units | Placebo | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | urate | 0.8861 | scaled units | High-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | urate | 0.8879 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | urate | 0.8900 | scaled units | High-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | urate | 0.8938 | scaled units | High-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | urate | 0.8939 | scaled units | High-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | urate | 0.8944 | scaled units | Placebo | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | urate | 0.8950 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | urate | 0.8954 | scaled units | High-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | urate | 0.8989 | scaled units | Low-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | urate | 0.9067 | scaled units | High-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | urate | 0.9093 | scaled units | High-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | urate | 0.9107 | scaled units | Low-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | urate | 0.9123 | scaled units | Low-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | urate | 0.9140 | scaled units | Placebo | -0.5HR |
| Reversed phase NEGATIVE ION MODE | urate | 0.9145 | scaled units | High-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | urate | 0.9164 | scaled units | Placebo | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | urate | 0.9167 | scaled units | High-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | urate | 0.9178 | scaled units | Placebo | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | urate | 0.9237 | scaled units | Low-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | urate | 0.9269 | scaled units | High-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | urate | 0.9296 | scaled units | Low-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | urate | 0.9309 | scaled units | Low-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | urate | 0.9323 | scaled units | High-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | urate | 0.9346 | scaled units | High-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | urate | 0.9379 | scaled units | High-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | urate | 0.9395 | scaled units | Low-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | urate | 0.9451 | scaled units | High-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | urate | 0.9468 | scaled units | Placebo | BASELINE |
| Reversed phase NEGATIVE ION MODE | urate | 0.9530 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | urate | 0.9637 | scaled units | Placebo | -0.5HR |
| Reversed phase NEGATIVE ION MODE | urate | 0.9681 | scaled units | High-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | urate | 0.9688 | scaled units | High-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | urate | 0.9777 | scaled units | High-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | urate | 0.9780 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | urate | 0.9818 | scaled units | High-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | urate | 0.9818 | scaled units | High-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | urate | 0.9839 | scaled units | Low-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | urate | 0.9845 | scaled units | Placebo | -0.5HR |
| Reversed phase NEGATIVE ION MODE | urate | 0.9868 | scaled units | High-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | urate | 0.9875 | scaled units | Low-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | urate | 0.9879 | scaled units | High-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | urate | 0.9969 | scaled units | Placebo | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | urate | 0.9990 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | urate | 1.0000 | scaled units | High-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | urate | 1.0031 | scaled units | Placebo | BASELINE |
| Reversed phase NEGATIVE ION MODE | urate | 1.0052 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | urate | 1.0059 | scaled units | Low-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | urate | 1.0078 | scaled units | High-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | urate | 1.0120 | scaled units | High-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | urate | 1.0172 | scaled units | Placebo | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | urate | 1.0175 | scaled units | High-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | urate | 1.0177 | scaled units | High-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | urate | 1.0255 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | urate | 1.0272 | scaled units | High-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | urate | 1.0365 | scaled units | Low-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | urate | 1.0440 | scaled units | Placebo | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | urate | 1.0525 | scaled units | High-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | urate | 1.0538 | scaled units | High-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | urate | 1.0552 | scaled units | Placebo | BASELINE |
| Reversed phase NEGATIVE ION MODE | urate | 1.0602 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | urate | 1.0658 | scaled units | Low-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | urate | 1.0764 | scaled units | Placebo | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | urate | 1.0826 | scaled units | Placebo | BASELINE |
| Reversed phase NEGATIVE ION MODE | urate | 1.0852 | scaled units | Low-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | urate | 1.0892 | scaled units | Placebo | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | urate | 1.0898 | scaled units | Placebo | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | urate | 1.0906 | scaled units | Low-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | urate | 1.0966 | scaled units | Placebo | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | urate | 1.0967 | scaled units | High-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | urate | 1.0993 | scaled units | Low-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | urate | 1.1066 | scaled units | Low-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | urate | 1.1075 | scaled units | High-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | urate | 1.1097 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | urate | 1.1134 | scaled units | Placebo | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | urate | 1.1155 | scaled units | High-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | urate | 1.1161 | scaled units | High-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | urate | 1.1166 | scaled units | Placebo | BASELINE |
| Reversed phase NEGATIVE ION MODE | urate | 1.1197 | scaled units | Placebo | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | urate | 1.1202 | scaled units | Placebo | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | urate | 1.1213 | scaled units | Placebo | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | urate | 1.1340 | scaled units | High-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | urate | 1.1345 | scaled units | Low-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | urate | 1.1354 | scaled units | Placebo | -0.5HR |
| Reversed phase NEGATIVE ION MODE | urate | 1.1408 | scaled units | Low-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | urate | 1.1444 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | urate | 1.1456 | scaled units | High-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | urate | 1.1459 | scaled units | Low-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | urate | 1.1465 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | urate | 1.1467 | scaled units | High-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | urate | 1.1492 | scaled units | Placebo | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | urate | 1.1503 | scaled units | Low-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | urate | 1.1509 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | urate | 1.1538 | scaled units | Placebo | -0.5HR |
| Reversed phase NEGATIVE ION MODE | urate | 1.1599 | scaled units | Low-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | urate | 1.1606 | scaled units | Placebo | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | urate | 1.1624 | scaled units | High-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | urate | 1.1631 | scaled units | Low-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | urate | 1.1649 | scaled units | Low-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | urate | 1.1654 | scaled units | High-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | urate | 1.1662 | scaled units | Low-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | urate | 1.1765 | scaled units | Placebo | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | urate | 1.1772 | scaled units | Placebo | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | urate | 1.1780 | scaled units | Low-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | urate | 1.1807 | scaled units | Placebo | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | urate | 1.1819 | scaled units | Placebo | -0.5HR |
| Reversed phase NEGATIVE ION MODE | urate | 1.1900 | scaled units | Placebo | -0.5HR |
| Reversed phase NEGATIVE ION MODE | urate | 1.1911 | scaled units | Low-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | urate | 1.1953 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | urate | 1.2002 | scaled units | Placebo | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | urate | 1.2103 | scaled units | Placebo | BASELINE |
| Reversed phase NEGATIVE ION MODE | urate | 1.2110 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | urate | 1.2138 | scaled units | Low-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | urate | 1.2145 | scaled units | Placebo | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | urate | 1.2172 | scaled units | Placebo | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | urate | 1.2248 | scaled units | Low-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | urate | 1.2274 | scaled units | Low-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | urate | 1.2311 | scaled units | Placebo | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | urate | 1.2339 | scaled units | Low-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | urate | 1.2347 | scaled units | Placebo | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | urate | 1.2347 | scaled units | Placebo | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | urate | 1.2492 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | urate | 1.2587 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | urate | 1.2616 | scaled units | Low-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | urate | 1.2702 | scaled units | Placebo | BASELINE |
| Reversed phase NEGATIVE ION MODE | urate | 1.2728 | scaled units | Placebo | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | urate | 1.3022 | scaled units | Placebo | -0.5HR |
| Reversed phase NEGATIVE ION MODE | urate | 1.3207 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | urate | 1.3463 | scaled units | High-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | urate | 1.4466 | scaled units | High-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | urate | 1.4501 | scaled units | Placebo | BASELINE |
| Reversed phase NEGATIVE ION MODE | urate | 1.4547 | scaled units | Placebo | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | urate | 1.4748 | scaled units | Placebo | -0.5HR |
| Reversed phase NEGATIVE ION MODE | urate | 1.4949 | scaled units | High-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | urate | 1.5009 | scaled units | Placebo | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | urate | 1.5017 | scaled units | Placebo | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | urate | 1.5343 | scaled units | High-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | urate | 1.5354 | scaled units | Placebo | +71HR POST INFUSION |
- UCSD Metabolomics Workbench, a resource sponsored by the Common Fund of the National Institutes of Health
|